Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

BJDX

Bluejay Diagnostics Inc

Sep 12 • 04:00PM ET

1.57

+0.10 6.80 %

Healthcare • Medical Devices • USA • NASD

Peers: DXCM ABT EXAS GH BIO QDEL QGEN NTRA MYGN FLGT

Index	-	P/E	-	EPS (ttm)	-38.98	Insider Own	0.30%	Shs Outstand	1.49M	Perf Week	8.28%
Market Cap	2.35M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	1.49M	Perf Month	13.77%
Enterprise Value	-1.91M	PEG	-	EPS next Q	-	Inst Own	6.63%	Short Float	7.14%	Perf Quarter	-11.30%
Income	-19.96M	P/S	-	EPS this Y	-	Inst Trans	0.07%	Short Ratio	0.06	Perf Half Y	-60.55%
Sales	0.00M	P/B	0.44	EPS next Y	-	ROA	-78.03%	Short Interest	0.11M	Perf YTD	-67.76%
Book/sh	3.54	P/C	0.53	EPS next 5Y	-	ROE	-96.69%	52W High	12.45 -87.39%	Perf Year	-78.34%
Cash/sh	2.97	P/FCF	-	EPS past 3/5Y	56.50% 26.06%	ROIC	-372.20%	52W Low	1.26 24.60%	Perf 3Y	-99.98%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.16% 6.40%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	98.25%	Oper. Margin	-	ATR (14)	0.10	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.56	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	59.29	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	4.56	EPS Q/Q	99.45%	SMA20	12.18%	Beta	0.50	Target Price	12800.00
Payout	-	Debt/Eq	0.03	Sales Q/Q	-	SMA50	4.84%	Rel Volume	0.20	Prev Close	1.47
Employees	7	LT Debt/Eq	0.01	Earnings	-	SMA200	-41.98%	Avg Volume	1.70M	Price	1.57
IPO	Nov 10, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	-155.21% -	Trades		Volume	334,569	Change	6.80%

Aug-11-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +34.29%
Aug-07-25 06:30PM	Bluejay Diagnostics Provides Second Quarter Business and Corporate Update (GlobeNewswire)
Jun-03-25 04:05PM	Bluejay Diagnostics Provides Mid-Year Business and Corporate Update (GlobeNewswire)
Apr-15-25 07:00AM	Bluejay Announces Abstract Accepted for Presentation at the 2025 Society of Academic Emergency Medicine (SAEM) Annual Meeting (GlobeNewswire)
Apr-07-25 05:21PM	Bluejay Diagnostics Announces Entry into Warrant Inducement Transaction for Approximately $3.7 Million in Gross Proceeds (GlobeNewswire) +112.46% -60.67%
05:10PM	Loading…
Nov-13-24 05:10PM	Bluejay Diagnostics Announces Reverse Stock Split (GlobeNewswire) -28.85%
Jun-28-24 11:32AM	Bluejay Diagnostics Announces Closing of $8.75 Million Underwritten Public Offering (GlobeNewswire) -6.77%
Jun-27-24 08:58AM	Bluejay Diagnostics Announces Pricing of $8.75 Million Underwritten Public Offering (GlobeNewswire) -53.99%
07:34AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace)
Jun-26-24 08:00AM	SYMON-I Study of Symphony IL-6 Suggests Prediction of Mortality in Sepsis Patients (GlobeNewswire) -40.73%
Jun-17-24 08:00AM	Bluejay Diagnostics Announces Reverse Stock Split (GlobeNewswire) -20.43%
07:40AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
Mar-28-24 11:53PM	BJDX Stock Earnings: Bluejay Diagnostics Misses EPS for Q4 2023 (InvestorPlace)
Jan-02-24 05:58PM	Bluejay Diagnostics Announces Closing of $3.5 Million Public Offering (GlobeNewswire)
Dec-28-23 08:00AM	Bluejay Diagnostics Announces Pricing of $3.5 Million Public Offering (GlobeNewswire) -32.48%
09:00AM	Loading…
Dec-27-23 09:00AM	Bluejay Diagnostics, Inc. Announces Initiation of Multicenter Clinical Study Evaluating Symphony IL-6 in Sepsis Patients (SYMON Study) (GlobeNewswire) -32.50%
Nov-09-23 04:05PM	Bluejay Diagnostics, Inc. Reports Third Quarter 2023 Financial Results (GlobeNewswire) +5.71%
Aug-28-23 07:59AM	BJDX: FDA Meeting Confirms Pathway (Zacks)
Aug-25-23 08:00AM	Bluejay Diagnostics Announces $1.59 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules (GlobeNewswire) -18.63%
Aug-16-23 07:00AM	Bluejay Diagnostics Announces Clinical Update and Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-10-23 04:05PM	Bluejay Diagnostics Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
Jul-24-23 08:30AM	Will Bluejay Diagnostics (NASDAQ:BJDX) Spend Its Cash Wisely? (Simply Wall St.) +42.36%
Jul-21-23 07:00AM	Bluejay Diagnostics Announces Reverse Stock Split (GlobeNewswire) +16.31%
May-31-23 06:36AM	BJDX: Orchestrating a New Testing Standard (Zacks Small Cap Research) +22.94%
May-19-23 07:00AM	Bluejay Diagnostics Updates Symphony IL-6 Regulatory Strategy (GlobeNewswire)
May-10-23 07:30AM	Bluejay Diagnostics Reports First Quarter 2023 Financial Results (GlobeNewswire)
Mar-20-23 04:15PM	Bluejay Diagnostics Reports 2022 Financial Results (GlobeNewswire) -16.40%
Feb-16-23 08:00AM	Bluejay Diagnostics Signs Collaboration Agreement with Blood Centers of America (GlobeNewswire) +8.75%
Nov-13-22 08:01AM	Bluejay Diagnostics, Inc. (NASDAQ:BJDX) drops to US$14m and insiders who purchased earlier this year lose another US$65k (Simply Wall St.)
Nov-09-22 08:00AM	Bluejay Diagnostics, Inc. Reports Third Quarter 2022 Financial Results (GlobeNewswire) -8.03%
04:05PM	Loading…
Aug-30-22 04:05PM	Bluejay Diagnostics, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-24-22 06:09AM	Here's Why We're Watching Bluejay Diagnostics' (NASDAQ:BJDX) Cash Burn Situation (Simply Wall St.)
Aug-16-22 07:30AM	Bluejay Diagnostics, Inc. to Host Key Opinion Leader Event on IL-6 Testing in Critical Care Settings: The Emerging Use of Biomarkers in Contemporary Management of COVID-19/Respiratory Failure (GlobeNewswire)
Jul-27-22 07:30AM	Positive Clinical Results for Bluejays Symphony IL-6 Test Presented at AACC 2022 (GlobeNewswire) -17.73%
Jul-26-22 04:30PM	Bluejay Diagnostics, Inc. Reports Second Quarter 2022 Financial Results (GlobeNewswire) +13.25%
Jul-06-22 07:30AM	Bluejay Completes Planned Clinical Studies for Symphony IL-6 Test (GlobeNewswire) +7.48%
Jun-09-22 07:30AM	Bluejay Reports FDA Agrees to Consider its Plan to Pursue a De Novo Regulatory Pathway for the Symphony IL-6 Test (GlobeNewswire) +26.36%
May-05-22 11:21AM	As Bluejay Diagnostics, Inc. (NASDAQ:BJDX) gains 41%, insiders who bought last year may be wishing they had bet higher (Simply Wall St.) -5.67%
Apr-20-22 04:10PM	Bluejay Diagnostics, Inc. Reports First Quarter 2022 Financial Results (GlobeNewswire)
Mar-28-22 07:00AM	Bluejay Diagnostics Appoints Edwin Rule as Vice President, Regulatory, Quality and Compliance (GlobeNewswire)
Mar-24-22 07:00AM	Bluejay Diagnostics Appoints Kenneth Fisher as Chief Financial Officer (GlobeNewswire) -6.87%
Mar-17-22 06:53AM	Companies Like Bluejay Diagnostics (NASDAQ:BJDX) Are In A Position To Invest In Growth (Simply Wall St.)
Mar-10-22 07:00AM	Bluejay Diagnostics, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update (GlobeNewswire) -6.51%
Jan-31-22 07:00AM	Bluejay Diagnostics, Inc. Announces its Pre-Submission Filing Package for the Symphony IL-6 Test is with the FDA (GlobeNewswire) +5.77%
Jan-13-22 11:29AM	Bluejay Diagnostics, Inc. Completes 90 Subjects in Multicenter Clinical Study Addressing Rapid IL-6 Test for COVID-19 Patients in Critical Care (GlobeNewswire)
Jan-11-22 04:19PM	10 Low-Float Penny Stocks for Steel-Gutted Investors (InvestorPlace)
Jan-05-22 08:15AM	Bluejay Diagnostics, Inc. Appoints Mark Feinberg, M.D. as Chief Medical Advisor (GlobeNewswire)
Dec-16-21 09:11AM	Bluejay Diagnostics, Inc. Reports Third Quarter 2021 Financial Results (GlobeNewswire)
Dec-07-21 07:25AM	Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
Nov-10-21 08:15AM	Bluejay Diagnostics, Inc. Announces Pricing of Upsized $21.6 Million Initial Public Offering (GlobeNewswire)

Bluejay Diagnostics, Inc. operates as a diagnostic company. It develops and markets minimally-invasive Point-of-Care diagnostics tests and devices that provide patients and providers with access to affordable and timely healthcare. It focus is on the infectious disease, inflammation, and oncology markets. The company was founded by Svetlana Dey and Dey Indraneil on March 20, 2015 and is headquartered in Acton, MA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BJDX

Bluejay Diagnostics Inc

Upgrade your FINVIZ experience